Shares in Swiss biotech Idorsia (SIX: IDIA) were down 6% on Monday morning, after the firm announced negative results from the Phase III MODIFY trial of lucerastat.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,